@article{1215c75e19744bfb8d4bbc4af600deaa,
title = "The Science Behind Biosimilars: Entering a New Era of Biologic Therapy",
author = "{on behalf of the American College of Rheumatology} and Bridges, {S. Louis} and White, {Douglas W.} and Worthing, {Angus B.} and Gravallese, {Ellen M.} and O'Dell, {James R.} and Kamala Nola and Jonathan Kay and Cohen, {Stanley B.}",
note = "Funding Information: Dr. Gravallese has received consulting fees from Eli Lilly and Company, Sanofi, and Janssen (less than $10,000 each) and grant support from AbbVie, Eli Lilly and Company, and Pfizer. Dr. O{\textquoteright}Dell has received consulting fees from Medac and Coherus (less than $10,000 each). Dr. Kay has received consulting fees from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen Biotech, Merck Sharp & Dohme, Pfizer, Roche Laboratories, Samsung Bioepis, and UCB (less than $10,000 each) and from Amgen and Sandoz (more than $10,000 each). Dr. Cohen has received consulting fees from Amgen, Boehringer Ingelheim, Merck, Pfizer, and Sandoz (less than $10,000 each).",
year = "2018",
month = mar,
doi = "10.1002/art.40388",
language = "English (US)",
volume = "70",
pages = "334--344",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "3",
}